Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
The Lancet. Oncology|September 7, 2019
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trialJohannes Weller, Theophilos Tzaridis, Frederic Mack, et al.
Neuro-Oncology Advances|January 7, 2026
Distribution and prognostic significance of myelotoxicity in newly diagnosed glioblastoma in a real-life cohort: Time to treat more aggressively?Christoph Oster, Pia Reineck, Teresa Schmidt, et al.
BMC Cancer|July 31, 2026
Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF)Sied Kebir, Christoph Oster, Sandeep Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2016
Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human GlioblastomaRoman Reinartz, Shanshan Wang, Sied Kebir, et al.
Neuro-Oncology Advances|October 26, 2022
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastomaLazaros Lazaridis, Elisabeth Bumes, Dorothee Cäcilia Spille, et al.
Journal of Cancer Research and Clinical Oncology|May 30, 2018
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trialChristina Schaub, Sied Kebir, Nina Junold, et al.
Cancer Medicine|April 22, 2025
Temporal Muscle Thickness as a Prognostic Marker in a Real-Life Cohort of Newly Diagnosed MGMT Promoter Methylated Glioblastoma: A Multicentric Imaging AnalysisLazaros Lazaridis, Christoph Moenninghoff, Elisabeth Bumes, et al.
Neurological Research and Practice|July 24, 2025
Decoding glioblastoma survival: unraveling the prognostic potential of olfactory function in a prospective observational studyChristoph Oster, Aylin Matyar, Teresa Schmidt, et al.
Journal of Neuro-Oncology|July 21, 2019
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trialSied Kebir, Christina Schaub, Nina Junold, et al.
Pageof 8